Mineralys Therapeutics, Inc. (MLYS) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Mineralys Therapeutics, Inc. (MLYS) Earnings Overview
As of June 28, 2026, Mineralys Therapeutics, Inc. (MLYS) reported trailing twelve-month net income of -$152M, reflecting +37.4% year-over-year growth. The company earned $-1.83 per diluted share over the past four quarters.
Looking at the long-term picture, MLYS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2020.
Mineralys Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CORT ($48M net income, 13.1% margin), SPRB (-$37M net income), INVA ($504M net income, 63.8% margin), MLYS has comparable earnings metrics. Compare MLYS vs CORT →
MLYS Earnings vs Peers
Earnings metrics vs comparable public companies
MLYS Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$155M | +13.0% | -$171M | $-2.29 | - | - |
| 2024 | -$178M | -147.3% | -$192M | $-3.66 | - | - |
| 2023 | -$72M | -141.3% | -$85M | $-1.99 | - | - |
| 2022 | -$30M | -53.5% | -$31M | $-5.77 | - | - |
| 2021 | -$19M | -466.5% | -$19M | $-3.89 | - | - |
| 2020 | -$3M | - | -$3M | $-0.74 | - | - |
Download Data
Export MLYS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MLYS — Frequently Asked Questions
Quick answers to the most common questions about buying MLYS stock.
What is MLYS earnings per share (EPS)?
MLYS trailing twelve-month (TTM) diluted EPS is $-1.83, reflecting +37.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Mineralys Therapeutics, Inc.'s net income?
Mineralys Therapeutics, Inc. (MLYS) trailing twelve-month net income is $-152M as of 2025. Earnings grew +37.4% year-over-year.
Is MLYS profitable?
MLYS is not currently profitable on a TTM basis, reporting a net loss of $-152M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MLYS's earnings growth rate?
MLYS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are MLYS's profit margins?
Mineralys Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -36.9%.
Is MLYS growing earnings?
Yes, MLYS earnings are accelerating — EPS growth of +37.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-152M. Earnings momentum is strengthening.
What was MLYS's best earnings year?
Mineralys Therapeutics, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were MLYS's earnings last quarter?
MLYS's most recent reported quarter was Q1 2026. Net income was $-39M with diluted EPS of $-0.47. For a full breakdown of all quarters, see the quarterly earnings table on this page.